Azerbaijan allows the application of joint testing of two vaccines against COVID-19

Azerbaijan allows the application of joint testing of two vaccines against COVID-19
  • Clock-gray 15:50
  • calendar-gray 09 February 2021

On February 8, 2021, the Ministry of Health of the Republic of Azerbaijan has allowed the conduct of clinical studies in the Republic of Azerbaijan for the joint use of the vaccine "Sputnik V" and the vaccine developed by AstraZeneca jointly with Oxford University. These studies are expected to begin by the end of February this year, the Ministry of Health told APA.

Earlier, N.F. Gamaleya Scientific Research Institute, Russian Direct Investment Fund (RDIF), AstraZeneca, and R-Pharm Group of Companies signed a memorandum of cooperation with the participation of Russian President Vladimir Putin in the field of coronavirus vaccine development in December 2020.

The first joint applies of vaccines in the world is carried out within the framework of the protocol of clinical trial registered on December 24, 2020.

The researchers envisage evaluation of immunogenicity and safety of the combined application of the vaccine "Sputnik V" and the vaccine developed by AstraZeneca in collaboration with the University of Oxford. The research program will continue for 6 months in the territory of several countries. Involving 100 volunteers from each country in conducting of these researches is planned.

About Sputnik V

Sputnik V is the world’s first registered vaccine based on a well-studied human adenoviral vector-based platform. Sputnik V is already registered in more than 15 countries.

The ongoing Sputnik V post-registration clinical trial in Russia involved more than 31,000 volunteers. Phase 3 clinical trials of Sputnik V have been conducting in the UAE, India, Venezuela, and Belarus.

Sputnik V is one of the three vaccines in the world with an efficacy of over 90%. The Vaccine’s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two-dose vaccine). The lyophilized (dry) form of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.

Requests for vaccination of more than 1.2 billion people (2.4 billion doses as Sputnik V is a two-doze vaccine) with the Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.

apa-logo-mini

Other news